Skip to main
  1. Stocks
  2. CorMedix
  3. Forecast
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is supported by a compelling mix of resilient current cash generation and credible long-term diversification, even as DefenCath faces reimbursement and pricing volatility after the 2Q27 reset. The company’s 3Q26 results showed DefenCath revenue of $17M, Melinta revenue of $31M to $37.3M, and cash of about $355M, while management reiterated FY26 revenue of $325M to $345M and narrowed adjusted EBITDA to $130M to $140M, reinforcing near-term financial stability. Its outlook improves further as Rezzayo’s 1Q27 Priority Review, the planned 1Q27 Heron close, and potential Medicare Advantage contracting create multiple paths to offset DefenCath uncertainty and broaden the revenue base.

Bears say

Cormedix is facing a weakening fundamental outlook because DefenCath’s growth story is increasingly constrained by slow clinical enrollment, regulatory uncertainty, and a narrowing set of expansion opportunities, including the removal of TPN from valuation after an uncertain development path. Commercially, 3Q26 revenue fell to $54.5MM, while DefenCath sales of $17.2MM were below expectations after TDAPA, and management suspended 2027 guidance pending clearer visibility on pricing, utilization, and Medicare Advantage contracting. The bearish view is reinforced by concentration risk, potential pricing pressure from the 2026 TDAPA cliff, competition from generics, and the possibility that the company may need additional funding before sustainable profitability.

CorMedix (CRMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

CorMedix (CRMD) Analyst Forecast & Price Prediction

Get the latest CorMedix (CRMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CorMedix (CRMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 7 analysts, CorMedix (CRMD) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


CorMedix (CRMD) Analyst Forecast & Price Prediction

Get the latest CorMedix (CRMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CorMedix (CRMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CRMD stock data and trends